KLK3 and benign prostatic hyperplasia: In addition to patients with a small PV, α1-blockers appear to be more appropriate for BPH patients with lower baseline PSA levels; BPH patients with higher PSA levels appear to be more suitable for treatment with 5-ARIs or a combination of 5-ARIs and α1-blockers.